SESP_MER2.8_TX_PVLS_Supplememtal_Quarterly

SESP_MER2.8_TX_PVLS_Supplememtal_Quarterly

The TX_PVLS MER indicator provides data on clients who have received a viral load (VL) test in the last 12 months and the percentage of those clients who were virally suppressed at the most recent test. It does not, however, provide data on viral suppression among clients eligible to receive a VL test (coverage estimate). In order to estimate VL suppression coverage for all clients on ART, the PEPFAR Mozambique SI team uses TX_CURR from six months prior as a denominator. To date, the team has used manually abstracted data (PMTCT_ART Already on ART) from the ANC registries to estimate VL suppression among pregnant and breastfeeding women specifically. The team expressed a need for a more precise estimate of pregnant and breastfeeding women eligible for a VL test, extracted from SESP.


    • Related Articles

    • SESP_MER2.8_TX_PVLS_Supplememtal_Quarterly

      The TX_PVLS MER indicator provides data on clients who have received a viral load (VL) test in the last 12 months and the percentage of those clients who were virally suppressed at the most recent test. It does not, however, provide data on viral ...

    • SESP TX_PVLS Indicator Specification and Requirements_v3.9.4

      TX_PVLS, an indicator to monitor viral suppression, reports the percentage of ART patients with a suppressed viral load (VL) result (<1,000 copies/ml) documented in the medical or laboratory records/laboratory information systems (LIS) within the ...

    • SESP_TX_PVLS by Sources Report Specification and Requirements_v1.4

      TX_PVLS, an indicator to monitor viral suppression, reports the percentage of ART patients with a suppressed viral load (VL) result (<1000 copies/ml) documented in the medical or laboratory records/laboratory information systems (LIS) within the past ...

    • SESP_MER2.8_TEMP_Quarterly

      Report Template

    • SESP TX_RTT Indicators Specification and Requirements_v1.9.5

      The TX _RTT indicator reports the number of ART patients with no ARV drug pick-up for greater than 28 days since their last expected pick-up (who experienced an interruption in Treatment – IIT) during any previous reporting period, who successfully ...